PharmaFocus Today – Page 19 – media

This is a common industry practice

　　Red Star Capital Bureau reported on October 15th that last night, Sinocell(688520.SH) disclosed a plan for a private placement, with the total amount of funds raised not exceeding 900 million yuan, which will be used entirely to supplement working capital. 　　On September 5th, the Shanghai Stock Exchange issued an inquiry regarding SinocellTech’s private placement, requesting clarification on issues such as the company’s increasing sales expenses, patient welfare and care programs, and external donations. Yesterday, SinocellTech released its response report. 　　Red Star Capital Bureau noticed that in recent years, Sinocell has expanded its product sales by providing subsidies to patients. On October 15, Sinocell SecuritiesThe Ministry responded to the Red Star Capital Bureau, saying that providing large subsidies to patients is a common practice in the industry and is beneficial for companies to promote their products. 　　Previously, Sinocell was embroiled in a controversy over medical insurance fraud. In response, Sinocell’s securities ...
- Source: drugdu
- 88
- October 29, 2025
GlaxoSmithKline expands herpes zoster vaccine indications to children aged 18 and above

On October 14, a reporter from Interface News learned from GlaxoSmithKline that the China National Medical Products Administration has approved Shingrix (GlaxoSmithKline’s recombinant herpes zoster vaccine (CHO cells)) for the prevention of herpes zoster in adults aged 18 and above who have an increased risk of developing herpes zoster due to immunodeficiency or immunosuppression caused by known diseases or treatments (such as autologous hematopoietic stem cell transplantation). To date, Shingrix is the first and only vaccine approved by the China National Medical Products Administration for use in this population. This approval builds on the previous expansion of its indication for adults aged 50 and above. https://finance.eastmoney.com/a/202510143533562628.html
- Source: drugdu
- 75
- October 29, 2025
Huali Family-owned company Haihe Pharmaceuticals and Dapeng Pharmaceuticals have reached a licensing cooperation agreement

On October 16, the gorgeous familyShanghai Haihe Pharmaceutical Research and Development Co. , Ltd. (hereinafter referred to as “Haihe Pharmaceutical”), a joint venture of Huali Family Co., Ltd. (hereinafter referred to as “Huali Family”), and Taiho Pharmaceutical Co., Ltd. (hereinafter referred to as “Taiping Pharmaceutical”) have reached an exclusive licensing agreement in Japan for the independently developed PI3Kα inhibitor resolise (CYH33). This collaboration marks another in-depth collaboration between Haihe Pharmaceuticals and Dapeng Pharmaceuticals, following the development of Glumetinib. It focuses on the development, production, and commercialization of risolide in Japan. Under the agreement, Dapeng Pharmaceuticals will obtain exclusive rights to risolide in Japan, while Haihe Pharmaceuticals will receive an upfront payment, development and sales milestone payments, and royalties based on the drug’s sales in Japan. The cooperation on Resolisab is not accidental, but a renewed collaboration between Haihe Pharmaceuticals and Dapeng Pharmaceuticals based on trust. As early as last year, ...
- Source: drugdu
- 107
- October 28, 2025
Antibiotic resistance poses a threat to global health

The World Health Organization recently released the “2025 Global Antibiotic Resistance Monitoring Report” and warned that the problem of resistance to commonly used antibiotics is widespread around the world, and the increasing resistance to basic antibiotics poses an increasingly serious threat to global health. The report predicts that one in six laboratory-confirmed bacterial infections causing common infections worldwide will be resistant to antibiotic treatment by 2023. Between 2018 and 2023, antibiotic resistance increased in more than 40% of monitored pathogen-antibiotic combinations, with an average annual increase of 5% to 15%. The report, which collected data from more than 100 countries, published for the first time the data on the use of drugs for the treatment of urinary tract and gastrointestinal infections, blood flu,The report provides estimates of resistance to 22 antibiotics for infections and gonorrhea. The report covers eight common bacterial pathogens, including Acinetobacter baumannii and Escherichia coli, each of ...
- Source: drugdu
- 73
- October 28, 2025
Watson Biopharma’s 13-valent pneumococcal conjugate vaccine is now available in Malaysia

Recently, Yunnan Watson BioYuxi Watson Biotechnology Co. , Ltd., a subsidiary of Watson Biotechnology Co., Ltd. (hereinafter referred to as ” Watson Biotechnology ” ), and Pharmaniaga Lifescience Sdn. Bhd. (hereinafter referred to as “PLS”), a wholly-owned subsidiary of Pharmaniaga Berhad of Malaysia, have officially signed an agreement for the distribution and localized production of the 13-valent pneumococcal polysaccharide conjugate vaccine (hereinafter referred to as “13-valent pneumococcal conjugate vaccine” or “PCV-13”) in Malaysia. Under the agreement, PLS will serve as Watson Biotechnology’s partner in Malaysia, jointly promoting technology transfer, localized production, and commercialization of PCV-13. After in-depth business negotiations and technical exchanges, Watson Bio and PLS reached a consensus on core terms such as cooperation model and technology implementation path, and ultimately facilitated the signing of this cooperation agreement. PCV-13 effectively prevents invasive diseases caused by pneumococci, including pneumonia, meningitis, and bacteremia, providing critical protection for infants and children under six years old, particularly against ...
- Source: drugdu
- 119
- October 28, 2025
Canagliflozin tablets obtain drug registration certificate

Southern Finance reported on October 27 that Huahai Pharmaceutical(600521) announced on October 27 that the company recently received the “Drug Registration Certificate” for canagliflozin tablets approved and issued by the State Food and Drug Administration. This product is used in combination with metformin hydrochloride: when blood sugar control is poor with metformin hydrochloride alone, it can be used in combination with metformin hydrochloride, combined with diet and exercise to improve blood sugar control in adult patients with type 2 diabetes; this product is used in combination with metformin hydrochloride and sulfonylurea drugs: when blood sugar control is poor with the combination of metformin hydrochloride and sulfonylurea drugs, it can be used in combination with metformin hydrochloride and sulfonylurea drugs, combined with diet and exercise to improve blood sugar control in adult patients with type 2 diabetes. Source：https://finance.eastmoney.com/a/202510273545770287.html
- Source: drugdu
- 75
- October 28, 2025
DREAMS-3, a Phase III clinical study of Masitutide head-to-head semaglutide, achieved its primary endpoint

On October 27, Innovent Biologics announced that the fourth Phase III clinical study (DREAMS-3) of its glucagon (GCG)/glucagon-like peptide-1 (GLP-1) dual receptor agonist, Mastolide (development code: IBI362), achieved its primary endpoint. The results demonstrated that among Chinese subjects with type 2 diabetes and obesity, 48.0% of subjects in the Mastolide group achieved HbA1c <7.0% and a 10% or greater weight loss from baseline at week 32, superior to the 21.0% in the semaglutide group (P < 0.0001). Furthermore, at week 32, the mean changes in HbA1c from baseline were 2.03% and 1.84% in the Mastolide and semaglutide groups, respectively, and the mean percentage reductions in weight from baseline were 10.29% and 6.00%, respectively (both P < 0.05). Source：https://finance.eastmoney.com/a/202510273544625429.html
- Source: drugdu
- 81
- October 28, 2025
Study finds bright nights raise risk for stroke and heart failure in adults over 40

In a recent study published in JAMA Network Open, researchers explored whether being exposed to light at nighttime is associated with a higher risk of developing heart disease, particularly for those of a specific age, sex, or genetic makeup. Their findings indicate that people over 40 exposed to bright lights at night face higher risks of heart disease, including stroke and heart failure. Associations were larger in females for heart failure and coronary artery disease, and in younger participants for heart failure and atrial fibrillation, with no clear modification for myocardial infarction or stroke. Background Healthy cardiovascular function relies on well-regulated circadian rhythms, which in turn influence vascular function, glucose tolerance, hormone levels, blood pressure, and heart rate. Disruption of these rhythms, through exposure to light or irregular sleep patterns, can elevate blood pressure and heart rate, increase inflammation, and reduce heart rate variability. Animal studies show that prolonged circadian ...
- Source: drugdu
- 82
- October 27, 2025
Semaglutide protects the heart beyond weight loss, SELECT trial shows

In a recent study published in The Lancet, researchers examined the associations between baseline adiposity measures, treatment-induced adiposity changes, and the risk of major adverse cardiovascular events (MACE) in the semaglutide effects on cardiovascular outcomes in people with overweight and obesity (SELECT) trial. Glucagon-Like Peptide 1 Receptor Agonists”>GLP-1RAs were initially developed for glycemic control in type 2 diabetes, and some have been effective in reducing cardiovascular risk and weight in people without diabetes. Obesity is a risk factor for cardiovascular mortality and morbidity, operating through metabolic, inflammatory, and hemodynamic pathways. Weight alone fails to capture differences between subcutaneous and visceral fat or distinguish between lean and fat mass. Visceral adiposity has been causally implicated in adverse cardiovascular outcomes. The relationship between baseline adiposity, treatment-induced changes in adiposity, and subsequent MACE is unclear in GLP-1RA trials. About the study In the present study, researchers investigated associations between baseline adiposity measures, treatment-induced ...
- Source: drugdu
- 115
- October 27, 2025
Tetasip, the first application!

On October 15, Rongchang Biopharma announced that its independently developed, first-in-class BLyS/APRIL dual-target fusion protein drug, Tetasip, for the treatment of primary immunoglobulin A (IgA) nephropathy has been accepted for marketing approval by the China Drug Administration (CDE) and has been placed under priority review. This marks Tetasip as the first domestically developed, research-driven new drug to be approved for marketing in the field of IgA nephropathy, bringing new hope to patients. Tetasip is the world’s first innovative dual-target fusion protein drug that simultaneously targets B-cell activating factor (BLyS) and proliferation-inducing ligand (APRIL). These two cytokines are significantly elevated in patients with IgA nephropathy, driving abnormal B cell activation, antibody class switching, and the production of pathogenic IgA. Ultimately, this leads to the deposition of immune complexes in the glomeruli, triggering inflammation and tissue damage. By simultaneously inhibiting BLyS and APRIL, Tetasip is able to reduce the number of mature ...
- Source: drugdu
- 106
- October 27, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.